A recent study published by the European Society of Cardiology found that smokers who reach age 70 lose approximately 4 years of life expectancy. The study tracked the health of over 7,000 older men and discovered a significant increase in mortality rates among current and former smokers compared to never-smokers.
Patients with three or more cardiovascular risk factors, including diabetes and hypertension, have a comparable stroke risk to those with atrial fibrillation. The study found that the risk of stroke associated with atrial fibrillation is eliminated in patients with five or more risk factors.
A large-scale study of 1 million patients found that high-dose statin use was associated with a significant reduction in the risk of developing dementia. The protective effect of statins remained consistent across different age, gender, and cardiovascular risk subgroups.
The study found that diabetic patients who received reperfusion therapy and secondary prevention medications had a lower ischemic stroke rate over time. Despite this improvement, diabetic patients were less likely to receive these treatments compared to non-diabetic patients.
A recent meta-analysis of 14 studies found that statin use is associated with a statistically significant decrease in cataract cases. The analysis suggests that younger individuals and those using statins for longer periods may benefit most from this effect.
A study found that short-term smoking cessation improves arterial function and reduces the risk of heart attacks, but doesn't immediately lower serotonin levels. However, longer-term smoking cessation may be needed to completely reverse the damage caused by smoking.
Research shows that general practitioners underdiagnose and undertreat women with atrial fibrillation (AF), particularly those with a high stroke risk. A study of over 15,000 French patients found that women were less likely to receive anticoagulant treatment than men, regardless of their age or comorbidities.
The study found a significant reduction in STEMI hospitalisations in Canton Ticino after the smoking ban was implemented, with an average 21.1% decrease between 2004-07 and 2007-2010. The impact varied by age group, with older people showing a long-lasting reduction in STEMI admissions.
A study found significant differences in LDL-cholesterol target achievement between Germany and the UK, with UK patients receiving more potent statins and higher doses. The UK system's incentive-based reimbursement may drive aggressive treatment, while Germany's restrictive system leads to conservative treatment.
A mass screening program in Sweden identified 5% of 75- to 76-year-olds with untreated atrial fibrillation. The study found that more than 90% of patients with newly diagnosed atrial fibrillation were started on oral anticoagulation treatment, which reduces the risk of stroke by up to 70%.
A CHADS2 score of 0 or 1 indicates a low stroke risk, but 35.8% of strokes occurred in patients with these scores, suggesting refined stratification is needed. The CHA2DS2-VASc score reclassified 53.8% of patients to higher risk categories.
A study of 2,238 CAD patients found that statin treatment reduced the risk of major cardiovascular events across all three groups: very low, low, and high LDL-C levels. Statins also showed significant benefits regardless of LDL-C level, suggesting their potential to reduce cardiovascular risk for all CAD patients.
The European Society of Cardiology emphasizes the need for personalized AF management to close the mortality gap. Current therapies have only improved mortality by 5-10%. A new taxonomy of AF is proposed based on its pathophysiology, and biomarkers, imaging, and ECG are being studied to improve treatment.
The European Society of Cardiology's ESC Congress 2013 received a record number of abstract submissions, with nearly 10,500 entries. The congress will feature four Hot Lines press conferences, discussing innovative treatments for conditions such as venous thromboembolism and myocardial infarction.
The European Society of Cardiology and Association for European Paediatric and Congenital Cardiology have released a joint consensus statement on pediatric arrhythmias. The statement outlines the diagnosis and management of pediatric arrhythmias, highlighting differences between pediatric and adult cases.
Cardiovascular screening is crucial for cancer patients who received chest radiation, especially those at high risk of developing radiation-induced heart disease (RIHD). The European Society of Cardiology recommends regular screenings to detect cardiac abnormalities and reduce the risk of death from coronary artery disease.
A study of 73,527 high blood pressure patients found that non-adherence to anti-hypertensive medication increases the risk of stroke and hospitalization. Patients who didn't take their medication correctly had a nearly four-fold increased risk of dying from stroke in the second year after first being prescribed drugs.
The European Society of Cardiology emphasizes the need for a resurgence in cardiovascular research and development to address the growing burden of cardiovascular diseases. The society proposes a forum to discuss ways to rejuvenate R&D, including simplifying regulation and increasing EU funding.
A large population study found that sufficient sleep increases the protective benefits of exercise, healthy diet, and non-smoking on cardiovascular disease. Adding sufficient sleep to these factors resulted in a 65% lower risk of composite CVD and an 83% lower risk of fatal events.
Researchers found that people who believe stress affects their health have double the risk of a heart attack. After adjusting for factors, they still had a 50% greater risk compared to those who didn't perceive stress as affecting their health.
The ISSUE III registry study found that cardiac pacing is more effective in patients with presumed neurally mediated syncope (NMS) and asystolic episodes, than in patients with positive tilt table testing. The registry showed that oral anticoagulation therapy is now widely used in patients with atrial fibrillation.
The new ESC Guidelines on Cardiac Pacing and Resynchronization Therapy offer a practical 'how-to' approach for users, including a logical decision tree and clinical perspectives. The guidelines aim to increase access to the latest evidence-based medicine for patients with cardiac arrhythmias and heart failure.
Death rates from heart disease have decreased in most EU countries since the early 1980s, but some nations are experiencing a slowdown in progress due to rising obesity and diabetes rates. The study found that cardiovascular disease remains a leading cause of death in Europe, with significant variation between individual countries.
A study by the European Society of Cardiology found that excessive cola consumption can cause unusual syncope and symptoms of arrhythmia due to high fructose corn syrup content and caffeine effects. Consuming honey made from Rhododendron pollen may also lead to similar issues.
The GAP-AF study found that complete ablation with complete linear lesions around pulmonary veins was more effective than incomplete lesions in preventing AF recurrence. This approach resulted in higher success rates and longer periods of sinus rhythm compared to incomplete procedures.
A new study finds a U-shaped association between fish consumption and atrial fibrillation risk, with moderate intakes offering the greatest protection. The lowest risk was found in individuals consuming around 0.63g of marine n-3 polyunsaturated fatty acids per day, corresponding to two servings of fatty fish per week.
The EHRA White Book reports on arrhythmia treatments in 55 ESC member countries, with a focus on lead extractions. Lead extraction data reveals significant morbidity and mortality worldwide.
Patients with paroxysmal atrial fibrillation (AF) show signs of depression, sleeping disorders, and low levels of physical activity, despite physicians rating their quality of life higher. Good communication between physicians and patients is crucial for adherence to medications and long-term prognosis.
The 2013 guidelines recommend a single systolic blood pressure target of 140 mmHg, with an increased role for home blood pressure monitoring. They also stress the importance of assessing totality of risk factors and consider individualized treatment approaches. Lifestyle changes, such as reducing salt and alcohol intake, are crucial fo...
A study published in the European Heart Journal found that cross-country skiers who completed more races and had faster finishing times were at a higher risk of developing arrhythmia. The risk was 30% higher for those completing five or more races, with an increased risk of atrial fibrillation and bradyarrhythmia.
A nationwide study in Sweden found that people with Alzheimer's disease taking cholinesterase inhibitors have a 36% lower risk of death, 38% lower risk of heart attack, and 26% lower risk of cardiovascular deaths compared to non-users. Patients on the highest recommended doses had the lowest risk of heart attack or death.
A new study presented at Heart Failure 2013 found that ambulatory levosimendan improved event-free survival by 50% compared to placebo in patients with end-stage heart failure. However, it failed to show significant improvements in functional capacity and quality of life.
The RELAX-AHF trial demonstrated serelaxin's efficacy in relieving dyspnea in HFpEF patients, particularly within the first 24 hours. The VIVIDD trial also showed vildagliptin to be non-inferior to placebo in improving LVEF in HFrEF patients with type 2 diabetes.
Researchers analyzed nearly 1 million heart failure admissions over 14 years, finding mortality and length of stay peak in January and Friday admissions. The study suggests staffing levels may contribute to seasonal variations in mortality and length of stay for these patients.
Research presented at the Heart Failure Congress 2013 found that heart failure accelerates the natural process of aging and favours early onset of male 'menopause', also known as andropausal syndrome. The prevalence of AS was four times higher in men with heart failure compared to healthy peers.
A randomized double-blind trial showed that Coenzyme Q10 decreases all-cause mortality by half, improving survival in severe heart failure patients. The study found that CoQ10 also significantly lowers cardiovascular mortality and hospitalizations for heart failure.
A multicentre Asian registry reported early experience confirming TAVI efficacy and safety in a physically smaller population. Low stroke and mortality rates were observed, with high procedural success rates, supporting the feasibility of TAVI in Asian patients.
A new investigational device, Helio System (TF-FA), was successfully deployed in four patients with high-risk aortic insufficiency. The device helps stabilize the Sapien XT Transcatheter Heart Valve and improves aortic insufficiency from moderate to trivial.
A study found that routinely measuring fractional flow reserve (FFR) during coronary angiography changes the management of one in four patients with stable angina, according to results from the RIPCORD trial. The use of FFR led to a change in the judgement of whether a coronary artery had a 'significant' lesion in 64 patients.
The Lotus Valve System demonstrated successful valve implantation in all 60 patients, meeting the primary device performance endpoint. The rate of moderate or greater aortic regurgitation decreased significantly, while mortality rates remained low.
The SOURCE XT post-approval study reported good clinical outcomes with high rates of device success for all access approaches, valve sizes, and delivery systems. Patients showed sustained improvement in effective orifice area and low rates of aortic regurgitation, with low one-year mortality and stroke rates.
The DESolve bioresorbable scaffold system demonstrates good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months. Early vessel restoration is indicated by significant increases in vessel, scaffold, and luminal areas.
A recent substudy found that the biodegradable stent Orsiro was non-inferior to the drug-eluting Xience Prime for in-stent late lumen loss at nine months, with similar rates of target lesion failure and reduced neointimal hyperplasia.
A large observational study questions whether bivalirudin is superior to heparin in the absence of GPIIb/IIIa blockade, showing similar 30-day mortality rates. The study found no evidence that treatment with bivalirudin improves outcome compared to heparin alone.
The European Heart Rhythm Association (EHRA) is introducing late-breaking clinical trials for the first time at its annual meeting, EHRA EUROPACE 2013. These trials focus on innovative treatments for atrial fibrillation and other arrhythmias.
Researchers found that PRRT decreases inflammation in atherosclerotic plaques, as measured by DOTATATE PET/CT, suggesting potential therapeutic benefits for cardiovascular disease. The study suggests that this treatment may reduce the occurrence of heart attacks by lowering inflammation levels.
A new stress test protocol investigating reduced perfusion imaging in low-risk patients undergoing SPECT myocardial perfusion imaging has been found to be diagnostically safe. The study predicted that using exercise ECG stress testing alone would have no adverse effects on prognosis at five years.
The ESC guide offers practical advice on using new oral anticoagulants (NOACs) to prevent stroke in patients with non-valvular atrial fibrillation. It highlights the benefits of NOACs, including reduced monitoring requirements and lower bleeding risk compared to vitamin K antagonists.
The European Society of Cardiology recommends catheter-based renal denervation for patients with resistant hypertension, indicating its potential in treating multiple cardiovascular diseases. The technique involves radiofrequency ablation to reset renal blood pressure regulation and reduce whole-body sympathetic nerve activity.
Two studies presented at EuroPRevent 2013 found that physically demanding work increases the risk of coronary heart disease. The research suggests that job strain and high physical demands may exacerbate cardiovascular risks, even when leisure-time activity is taken into account.